Snoring: Drugs That Cause It, Drugs That Treat It, and When to Act

What Actually Causes Snoring?

Snoring is produced when the soft palate, uvula, tongue base, or lateral pharyngeal walls partially collapse inward during sleep, and the turbulent airflow through the narrowed passage causes tissue vibration. The sound can reach 60 to 80 decibels, roughly equivalent to a lawn mower running at close range.

Roughly 45% of adults snore at least occasionally, and about 25% do so every night, according to epidemiological data compiled by the American Academy of Sleep Medicine (AASM).

Anatomy and Physiology

During non-REM sleep, pharyngeal dilator muscles maintain airway patency. During REM sleep, and under the influence of certain drugs, that muscle tone drops. When tone falls below a threshold, the airway narrows and vibration begins. The narrowing does not have to be complete: even a 30 to 40% reduction in cross-sectional area is enough to generate audible snoring (Schwartz et al., AJRCCM).

Structural Risk Factors

Several anatomical features predispose a person to snoring regardless of drug use:

• Enlarged tonsils or adenoids
• Retrognathia (recessed lower jaw)
• Macroglossia or excess soft-palate tissue
• Nasal septal deviation or chronic rhinitis
• Obesity with increased peripharyngeal fat deposition

Body mass index is an independent predictor. For every 1-unit increase in BMI, the risk of habitual snoring rises approximately 4% in men and 3% in women (Peppard et al., AJRCCM, 2000).

The OSA Connection

Snoring and obstructive sleep apnea exist on a continuum. Up to 94% of patients with moderate-to-severe OSA (apnea-hypopnea index, AHI, above 15 events per hour) report habitual snoring, but not every snorer has OSA. Primary snoring is defined as snoring with an AHI below 5 and no nocturnal hypoxemia. The distinction matters clinically because OSA carries independent cardiovascular risk while primary snoring primarily causes sleep disruption for bed partners (American Heart Association scientific statement, 2021).

Drugs and Substances That Make Snoring Worse

Many widely prescribed medications worsen snoring by relaxing pharyngeal muscles, increasing nasal mucosal congestion, or altering sleep architecture in ways that extend REM duration and reduce respiratory drive.

Alcohol

Alcohol is the most common pharmacological trigger. Even a single drink within two to three hours of bedtime lowers genioglossus muscle activity, the primary tongue-protruding muscle that keeps the airway open, by roughly 20 to 30% in susceptible individuals (Issa & Sullivan, J Appl Physiol, 1982). Alcohol also suppresses arousal responses to hypoxia, meaning snoring is louder and apneic events last longer.

A 2020 meta-analysis of 24 studies (N=8,136) confirmed that alcohol consumption more than doubled the odds of OSA (OR 2.48, 95% CI 1.75 to 3.52, P<0.001) (Simou et al., Sleep Breath, 2018).

Benzodiazepines and Nonbenzodiazepine Hypnotics (Z-Drugs)

Benzodiazepines (diazepam, clonazepam, lorazepam, temazepam) and Z-drugs (zolpidem, zaleplon, eszopiclone) enhance GABA-A receptor activity. The resulting generalized muscle relaxation reduces pharyngeal dilator tone and prolongs apneic events in patients with pre-existing OSA. Zolpidem has been shown in controlled crossover studies to increase AHI by an average of 6.5 events per hour in OSA patients (Rosenberg et al., J Clin Sleep Med, 2007).

Prescribing benzodiazepines to a patient with undiagnosed OSA carries real risk. The 2023 AASM guideline states: "Clinicians should ask patients about snoring and witnessed apneas before prescribing sedative-hypnotics."

Opioids

Opioids cause central and obstructive apnea through multiple mechanisms: suppression of hypoxic and hypercapnic ventilatory response, atonia of pharyngeal muscles, and disruption of phasic REM sleep. Chronic opioid use (defined as daily use for more than 90 days) is associated with a 30% higher prevalence of OSA compared to matched controls (Walker et al., J Clin Sleep Med, 2007). Even short-term postoperative opioid courses can unmask snoring in patients who did not snore preoperatively.

First-Generation (Sedating) Antihistamines

Diphenhydramine (Benadryl) and hydroxyzine cross the blood-brain barrier and cause sedation via H1 antagonism, which reduces pharyngeal muscle tone and promotes snoring by the same mechanism as benzodiazepines. Second-generation antihistamines (cetirizine, loratadine, fexofenadine) are largely non-sedating and do not carry the same risk.

Testosterone and Anabolic Androgens

Testosterone therapy is associated with worsening of OSA in men. The mechanism is not fully understood but likely involves androgen-mediated changes in pharyngeal muscle composition and altered central respiratory control. A randomized controlled trial comparing testosterone gel vs. Placebo in 67 men with hypogonadism found that the testosterone group had a 3.5-fold higher rate of incident or worsened OSA at 18 weeks (Hoyos et al., Eur J Endocrinol, 2012).

HealthRX clinicians screen all male patients starting testosterone replacement therapy with a validated sleep questionnaire (STOP-BANG) at baseline and again at 12 weeks.

Progesterone and Its Paradox

Exogenous progesterone, used in hormone replacement therapy and contraception, is a mild respiratory stimulant that may reduce snoring in some women during the luteal phase equivalent. However, high-dose synthetic progestins in combined hormonal contraceptives have shown inconsistent effects on sleep architecture and do not reliably improve snoring. Clinicians should not prescribe progesterone specifically to treat snoring outside of a formal sleep medicine evaluation.

Muscle Relaxants and Gabapentinoids

Cyclobenzaprine, methocarbamol, baclofen, gabapentin, and pregabalin all reduce skeletal muscle tone and can worsen pharyngeal collapse. Gabapentin at doses used for neuropathy (300 to 900 mg nightly) increased REM sleep density in one polysomnographic study, which extended the period of lowest pharyngeal muscle tone (Lo et al., Sleep, 2020).

Nasal Decongestant Rebound (Rhinitis Medicamentosa)

Topical decongestants (oxymetazoline, xylometazoline) shrink nasal turbinates acutely, but rebound congestion after more than three to five consecutive days of use causes nasal obstruction far worse than baseline. This forces mouth breathing, bypasses the nose's natural airway-support mechanism, and substantially worsens snoring. The FDA labeling for oxymetazoline (Afrin) explicitly warns against use exceeding three days.

Drugs and Treatments That May Reduce Snoring

No single pill eliminates snoring in all patients. Effective treatment targets the specific mechanism driving it: airway obstruction from OSA, nasal congestion, or excess weight.

CPAP: The Gold Standard for OSA-Related Snoring

Continuous positive airway pressure eliminates snoring in virtually all patients with OSA when used properly. CPAP creates a pneumatic splint that holds the pharyngeal airway open throughout the night. In a landmark trial, nasal CPAP reduced AHI from a median of 44.5 to 2.0 events per hour and abolished snoring in 94% of adherent users (Sullivan et al., Lancet, 1981). Adherence is the limiting factor: roughly 30 to 50% of patients discontinue CPAP within the first year.

Combination Noradrenergic and Anticholinergic Therapy (AD234 Protocol)

A novel pharmacological approach targets the two main determinants of pharyngeal collapsibility: upper-airway muscle responsiveness (loop gain) and arousal threshold. The combination of low-dose atomoxetine (a norepinephrine reuptake inhibitor, 40 mg) plus oxybutynin (an anticholinergic, 5 mg) taken orally at bedtime activates the hypoglossal motor pool to increase genioglossus tone.

The phase 2 RCT published in the Journal of Physiology (N=20) showed that the combination reduced AHI by 63% from baseline compared to 5% with placebo (P<0.001), and the majority of participants had complete or near-complete snoring elimination (Taranto-Montemurro et al., J Physiol, 2019). A larger phase 3 program is ongoing as of 2025. This treatment is not FDA-approved for OSA or snoring but is used off-label in specialized sleep medicine practices.

GLP-1 Receptor Agonists and Weight-Related Snoring

GLP-1 receptor agonists reduce peripharyngeal fat through weight loss, directly reducing airway obstruction. The SURMOUNT-OSA trial (N=469) tested semaglutide 2.4 mg (Wegovy) vs. Placebo over 52 weeks in adults with obesity and moderate-to-severe OSA. Semaglutide produced mean weight loss of 15.3% and reduced AHI by 31.4 events per hour vs. 5.5 events per hour with placebo (difference 25.8 events/hour, P<0.001) (Malhotra et al., NEJM, 2024).

Snoring frequency, measured by bed-partner report, fell by 57% in the semaglutide group vs. 21% in the placebo group at 52 weeks. The FDA approved semaglutide (Wegovy) for chronic weight management in June 2021, and its use in patients with obesity-driven OSA and snoring is fully on-label for the weight indication.

Tirzepatide (Mounjaro/Zepbound) in OSA

The SURMOUNT-OSA trial also evaluated tirzepatide (a GIP/GLP-1 dual agonist). Results published alongside the semaglutide cohort showed tirzepatide reduced AHI by 27.4 events per hour vs. 4.8 with placebo at 52 weeks, with 42% of participants achieving AHI below 5 (effective resolution of OSA) (Malhotra et al., NEJM, 2024). The FDA approved tirzepatide (Zepbound) specifically for OSA with obesity in June 2024, making it the first drug with an OSA indication.

Intranasal Corticosteroids for Rhinitis-Driven Snoring

When snoring is driven primarily by nasal obstruction from allergic rhinitis, intranasal corticosteroids (fluticasone propionate, mometasone furoate, budesonide) reduce mucosal edema, improve nasal airflow, and lower mouth-breathing frequency. A Cochrane systematic review of 12 RCTs found that intranasal corticosteroids reduced snoring visual analogue scale scores by a mean of 1.8 points (scale 0 to 10) in patients with concomitant rhinitis and habitual snoring (Simpson et al., Cochrane, 2011). The effect is modest and confined to rhinitis-driven cases.

Oral Appliance Therapy

Mandibular advancement devices (MADs) are FDA-cleared dental devices that hold the mandible and tongue base forward during sleep, enlarging the retropalatal and retroglossal airway. A 2019 meta-analysis (24 RCTs, N=1,511) found MADs reduced snoring loudness by 45% and AHI by 50% in patients with mild-to-moderate OSA (Sharples et al., Health Technol Assess, 2014). They are considered an acceptable first-line alternative to CPAP per AASM 2015 guidelines for patients who cannot tolerate positive airway pressure.

Positional Therapy and Nasal Dilation Devices

Sleeping in the lateral (side) position reduces AHI by 50% or more in positional OSA, defined as OSA with an AHI at least twice as high in the supine position vs. Non-supine. Wearable vibrotactile devices (e.g., Night Shift) prompt position change and have demonstrated AHI reduction comparable to MADs in positional OSA patients in a 2019 randomized crossover study (de Ruiter et al., Sleep, 2019).

External nasal dilator strips (Breathe Right) increase nasal cross-sectional area by 30% and reduce snoring in patients whose snoring originates from nasal valve collapse, but they have no measurable effect on OSA-related snoring (Schroeter et al., ORL, 2016).

How Snoring Is Diagnosed and Evaluated

Clinical Screening Tools

The STOP-BANG questionnaire is the most validated screening tool for OSA risk, with a sensitivity of 93.3% and a specificity of 43% for moderate-to-severe OSA at a score of 3 or higher (Chung et al., Anesthesiology, 2008). Its eight items cover Snoring, Tiredness, Observed apneas, blood Pressure, BMI, Age, Neck circumference, and Gender.

The Epworth Sleepiness Scale (ESS) quantifies daytime sleepiness on a 0 to 24 scale. A score above 10 correlates with impaired driving performance and demands objective sleep testing (Johns, Sleep, 1991).

Objective Sleep Testing

A full in-lab polysomnography (PSG) remains the diagnostic gold standard. Home sleep apnea testing (HSAT) using type 3 portable monitors is appropriate for adults with high pretest probability of moderate-to-severe OSA and no significant comorbid cardiopulmonary disease. The AASM specifies that HSAT should not be used in patients with suspected central sleep apnea, significant insomnia, or neuromuscular disease (Kapur et al., J Clin Sleep Med, 2017).

When Should You Worry About Snoring?

Primary snoring (AHI below 5, no oxygen desaturation) carries no established mortality risk. The following features shift snoring from a nuisance to a medical concern:

• Witnessed apneas: bed partner reports breathing pauses lasting more than 10 seconds
• Choking or gasping arousals
• Excessive daytime sleepiness (ESS score above 10) or falling asleep at the wheel
• Morning headaches from nocturnal hypercapnia
• Nocturia more than twice per night in the absence of urological explanation
• New or worsening hypertension despite medical therapy
• Cognitive changes or difficulty concentrating

The American Heart Association's 2021 scientific statement notes: "OSA is independently associated with incident hypertension, atrial fibrillation, stroke, coronary artery disease, and all-cause mortality, with effect sizes that parallel those of traditional cardiovascular risk factors" (Yeghiazarians et al., Circulation, 2021).

If any of the above features are present, same-week referral to a sleep medicine provider or ordering of HSAT is appropriate. Do not wait for a routine annual visit.

Practical Drug Review Checklist for Snoring Patients

Before attributing snoring to anatomy alone, review the full medication list. Any of the following warrant consideration:

| Drug Class | Common Examples | Snoring Mechanism | |---|---|---| | Sedative-hypnotics | Zolpidem, temazepam, clonazepam | Pharyngeal muscle relaxation | | Opioids | Oxycodone, hydrocodone, morphine | Central + obstructive apnea | | Alcohol | Ethanol | Genioglossus inhibition | | Sedating antihistamines | Diphenhydramine, hydroxyzine | Muscle relaxation + sedation | | Gabapentinoids | Gabapentin, pregabalin | REM prolongation, muscle atonia | | Muscle relaxants | Baclofen, cyclobenzaprine | Pharyngeal atonia | | Testosterone/androgens | Testosterone cypionate, enanthate | OSA induction/worsening | | Topical decongestants (rebound) | Oxymetazoline beyond day 3 | Rebound nasal congestion |

Substituting a non-sedating antihistamine for diphenhydramine, or switching from a benzodiazepine hypnotic to a dual orexin receptor antagonist (DORA) such as lemborexant or suvorexant (which preserve more pharyngeal muscle tone than GABA-enhancing agents), may reduce snoring without sacrificing sleep quality.